Transaction DateRecipientSharesTypePriceValue
17th February 2021Randal W Scott302,621Conversion of derivative$0.00
17th February 2021Genetic Disorder L.P. Kkr3,450,000Open or private sale$60.47$208,617,360.00
17th February 2021Randal W Scott334,546Conversion of derivative$0.00
17th February 2021Randal W Scott312,500Open or private purchase$16.00$5,000,000.00
17th February 2021Randal W Scott16,000Open or private purchase$62.50$1,000,000.00
17th February 2021Randal W Scott752,897Conversion of derivative$0.00
13th January 2021Uma Sinha4,934Open or private sale$124.72$615,362.07
13th January 2021Uma Sinha1,498Open or private sale$123.48$184,971.09
13th January 2021Uma Sinha572Open or private sale$122.27$69,936.55
13th January 2021Uma Sinha696Open or private sale$121.11$84,292.14
Bridge Bio Pharma
Bridge Bio Pharma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis.

Ticker: BBIO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1743881
Employees: 248
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags